tbuckley/cabot-search huggingface dataset:
Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive and ANCA‐Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets
Authors: Eli M. Miloslavsky, Na Lu, Sebastian Unizony, Hyon K. Choi, Peter A. Merkel, Philip Seo, Robert Spiera, Carol A. Langford, Gary S. Hoffman, Cees G. M. Kallenberg, E. William St.Clair, Nadia K. Tchao, Fernando Fervenza, Paul A. Monach, Ulrich Specks, John H. Stone
Journal: Arthritis & Rheumatology (2016)

Objective To examine the relationship of antineutrophil cytoplasmic antibody (ANCA) type and ANCA‐associated vasculitis (AAV) diagnosis with demographic features, disease manifestations, and clinical outcomes. We focused on patients who account for the differences between ANCA type and disease type classifications: anti‐myeloperoxidase (MPO)–ANCA–positive and ANCA‐negative patients with granulomatosis with polyangiitis (Wegener's) (GPA). Methods We performed a pooled analysis of the Wegener's Granulomatosis Etanercept Trial and the Rituximab in ANCA‐Associated Vasculitis trial comparing patients with MPO‐ANCA–positive GPA and patients with ANCA‐negative GPA to patients with proteinase 3 (PR3)–ANCA–positive GPA and patients with MPO‐ANCA–positive microscopic polyangiitis (MPA). Results Of the 365 patients analyzed, 273 (75%) had PR3‐ANCA–positive GPA, 33 (9%) had MPO‐ANCA–positive GPA, 15 (4%) had ANCA‐negative GPA, and 44 (12%) had MPO‐ANCA–positive MPA. MPO‐ANCA–positive GPA patients were younger at diagnosis compared to MPO‐ANCA–positive MPA patients (53 versus 61 years; P = 0.02). Their disease manifestations and rates of relapse were similar to those of PR3‐ANCA–positive GPA patients. Relapse was more frequent in MPO‐ANCA–positive GPA patients than in patients with MPO‐ANCA–positive MPA at trial entry as well as at 12 and 18 months. ANCA‐negative patients with GPA had lower Birmingham Vasculitis Activity Score for Wegener's Granulomatosis scores at trial entry than PR3‐ANCA–positive patients with GPA (4.5 versus 7.7; P &lt; 0.01), primarily because of a lower prevalence of renal involvement. Conclusion We were unable to demonstrate important clinical differences between MPO‐ANCA–positive and PR3‐ANCA–positive patients with GPA. The risk of relapse was associated more closely with disease type than with ANCA type in this patient cohort. These findings deserve consideration in the assessment of relapse risk in patients with AAV.
Leukemia Inhibitory Factor: A Newly Identified Chemoattractant and Regulator of Metastasis of Rhabdomyosarcomas and Neuroblastomas to Bone Marrow.
Authors: Marcin Wysoczynski, Kacper Jankowski, Kasia Miekus, Magda Kucia, Anna Janowska-Wieczorek, Janina Ratajczak, Mariusz Z. Ratajczak
Journal: Blood (2004)
Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease
Authors: Maria Rita Pitari, Marco Rossi, Cirino Botta, Eugenio Morelli, Annamaria Gullà, Eleonora Iuliano, Teresa Del Giudice, Nicola Amodio, Maria Teresa Di Martino, Fortunato Morabito, Pierosandro Tagliaferri, Pierfrancesco Tassone
Journal: Blood (2013)
ASXL1-Mutated Donor HSCs Evolved into FLT3-ITD Positive AML in the Unrelated Donor and FLT3-ITD Negative AML in the Recipient after Transplant
Authors: Zhongwen Liu, Hongxing Liu, Yanli Zhang, Dai Kong, Jie Shi, Yin Zhang, Meiying Wen, Yongping Song, Chunrong Tong, Mingyi Chen, William J. Murphy, Kai Sun
Journal: Blood (2015)
Phase I Study of IPH1101 (with Low Dose of IL-2) in Patient with B-NHL
Authors: Jean François Rossi, Valerie Rouillé, Sylvie Lafaye de Micheaux, Hélène Sicard, Olivier Pétricoul, Lucile Beautier, Christine d’Arnoux, Volker Kunzmann
Journal: Blood (2008)
Combination of the IGF-1 Receptor Inhibitor Picropodophylin and the BH3 Mimetic ABT-737 Has Synergistic Anti-Myeloma Activity
Authors: Liesbeth Bieghs, Ken Maes, Els Van Valckenborgh, Eline Menu, Hans Erik Johnsen, Mette Nyegaard, Helena Jernberg Wiklund, Karin Vanderkerken, Elke De Bruyne
Journal: Blood (2012)
Current Status on Cholangiocarcinoma and Gallbladder Cancer
Authors: Tomoki Ebata, Giorgio Ercolani, Domenico Alvaro, Dario Ribero, Luca Di Tommaso, Juan W. Valle
Journal: Liver Cancer (2016)

Cholangiocarcinomas (CC) as well as gallbladder cancers are relatively rare and intractable diseases. Clinical, pathological, and epidemiological studies on these tumors have been under investigation. The current status and/or topics on biliary tract cancers have been reported in the East West Association of Liver Tumor (EWALT), held in Milano, Italy in 2015.All the authors, herein, specifcally reported the current status and leading-edge findings on biliary tract cancers as the following sequence: epidemiology of CC, surgical therapy for intrahepatic CC, surgical therapy for perihilar CC, surgical therapy for gallblad der cancer, chemotherapy for biliary tract cancers, and new histological features in CC.The present review article will update the knowledge on biliary tract cancers, en hancing the quality of daily clinical practice. However, many features about these cancers remain unknown; further studies are required to establish disease-specific optimal treatment strategies.
Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Cladribine
Authors: Jerzy Z Blonski, Tadeusz Robak, Jacek Trelinski, Krzysztof Chojnowski, Krzysztof Warzocha, Ilona Seferynska, Lech Konopka, Bernadetta Ceglarek, Malgorzata Calbecka, Aleksandra Kostyra, Beata Stella-Holowiecka, Janusz Kloczko, Anna Dmoszynska, Malgorzata Kowal, Krzysztof Lewandowski, Jadwiga Dwilewicz-Trojaczek, Elzbieta Wiater, Kazimierz Kuliczkowski, Stanislaw Potoczek, Andrzej Hellmann, Andrzej Mital, Aleksander B. Skotnicki, Wieslaw Nowak, Kazimierz Sulek, Andrzej Zdunczyk, Krystyna Zawilska
Journal: Blood (2008)
Meta-Transcriptome of Bone Marrow Stem Cells Demonstrates Platform and Lab Dependant Variability in Gene Expression and Reveals a Novel Set of Enriched Genes.
Authors: Davendra Sohal, Andrew Yeatts, Joanna Opalinska, Li Zhou, Perry Pahanish, Kenny Ye, Maria Figueroa, John Mariadason, Ari Melnick, John Greally, Amit Verma
Journal: Blood (2006)
Abstract 5373: AK-1, a specific SIRT2 inhibitor, induces cell cycle arrest by downregulating Snail in HCT116 human colon carcinoma cells
Authors: MIN GYEONG CHEON, Ja-Eun Kim
Journal: Cancer Research (2015)

Abstract SIRT2, a member of the sirtuin family, is involved in the regulation of a variety of physiological functions. In addition, SIRT2 has been studied in the context of pathological conditions including neurodegenerative diseases, metabolic syndrome, and cancer. The effect of SIRT2 on cancer cell growth depends on cancer tissue type. To investigate the role of SIRT2 in colon cancer, we treated HCT116 human colon cancer cells with the SIRT2-specific inhibitor AK-1, a cell-permeable benzylsulfonamide. AK-1 treatment induced proteasomal degradation of the Snail transcription factor through inactivation of the NF-κB/CSN2 pathway. Reduction in the level of Snail resulted in upregulation of p21, a cyclin-dependent kinase inhibitor, leading to G1 arrest, slow proliferation, and slow wound-healing activity. The regulation of Snail-p21 axis by AK-1 also occurs in HT-29 colon cancer cells. Therefore, inhibition of SIRT2 using AK-1 would be a beneficial intervention in the treatment of colon cancer. Citation Format: MIN GYEONG CHEON, Ja-Eun Kim. AK-1, a specific SIRT2 inhibitor, induces cell cycle arrest by downregulating Snail in HCT116 human colon carcinoma cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5373. doi:10.1158/1538-7445.AM2015-5373
Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Authors: Azra Raza, Naomi Galili, Deborah Mulford, Scott E. Smith, Gail Brown, Lisa Meng, David P. Steensma, Roger M. Lyons, Ralph Boccia, Mikkael A. Sekeres, Guillermo Garcia-Manero, Ruben A. Mesa
Journal: Blood (2011)
A Phase II, Open-Label Pilot Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined with G-CSF in 12 Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Lymphoma - an Interim Analysis
Authors: Gayatri Setia, Nabil Hagog, Bita Jalilizeinali, Sharon Funkhouser, Loretta Pierzchanowski, Fengshuo Lan, Theodore G. Gabig, Bonnie Kiner-Strachan, Karen Kelleher, Ming-Chu Hsu, Li-Wen Chang, Michael W. Schuster
Journal: Blood (2015)
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer
Authors: Geert A. Cirkel, Paul Hamberg, Stefan Sleijfer, Olaf J. L. Loosveld, M. Wouter Dercksen, Maartje Los, Marco B. Polee, Franchette van den Berkmortel, Maureen J. Aarts, Laurens V. Beerepoot, Gerard Groenewegen, Martijn P. Lolkema, Metin Tascilar, Johanna E. A. Portielje, Frank P. J. Peters, Heinz-Josef Klümpen, Vincent van der Noort, John B. A. G. Haanen, Emile E. Voest
Journal: JAMA Oncology (2016)

To our knowledge, this is the first randomized clinical trial evaluating an alternating treatment regimen in an attempt to delay disease progression in clear cell renal cell carcinoma.To test our hypothesis that an 8-week rotating treatment schedule with pazopanib and everolimus delays disease progression, exhibits more favorable toxic effects, and improves quality of life when compared with continuous treatment with pazopanib.This was an open-label, randomized (1:1) study (ROPETAR trial). In total, 101 patients with treatment-naive progressive metastatic clear cell renal cell carcinoma were enrolled between September 2012 and April 2014 from 17 large peripheral or academic hospitals in The Netherlands and followed for at least one year.First-line treatment consisted of either an 8-week alternating treatment schedule of pazopanib 800 mg/d and everolimus 10 mg/d (rotating arm) or continuous pazopanib 800 mg/d (control arm) until progression. After progression, patients made a final rotation to either pazopanib or everolimus monotherapy (rotating arm) or initiated everolimus (control arm).The primary end point was survival until first progression or death. Secondary end points included time to second progression or death, toxic effects, and quality of life.A total of 52 patients were randomized to the rotating arm (median [range] age, 65 [44-87] years) and 49 patients to the control arm (median [range] age, 67 [38-82] years). Memorial Sloan Kettering Cancer Center risk category was favorable in 26% of patients, intermediate in 58%, and poor in 15%. Baseline characteristics and risk categories were well balanced between arms. One-year PFS1 for rotating treatment was 45% (95% CI, 33-60) and 32% (95% CI, 21-49) for pazopanib (control). Median time until first progression or death for rotating treatment was 7.4 months (95% CI, 5.6-18.4) and 9.4 months (95% CI, 6.6-11.9) for pazopanib (control) (P = .37). Mucositis, anorexia, and dizziness were more prevalent in the rotating arm during first-line treatment. No difference in quality of life was observed.Rotating treatment did not result in prolonged progression-free-survival, fewer toxic effects, or improved quality of life. First-line treatment with a vascular endothelial growth factor inhibitor remains the optimal approach in metastatic clear cell renal cell carcinoma.clinicaltrials.gov Identifier: NCT01408004.
Small Subcompartmentalized Microreactors as Support for Hepatocytes
Authors: Yan Zhang, Marie Baekgaard‐Laursen, Brigitte Städler
Journal: Advanced Healthcare Materials (2016)

Mimicking specific structural or functional aspects of cells is considered a promising approach to substitute for missing or lost cellular functions. However, the interaction of such artificial assemblies with their biological counterparts including the exploitation of the activity of the synthetic partner remains thus-far a rather unexplored avenue. Herein, the assembly of active microreactors with similar size to hepatocytes is reported. These microreactors are successfully cocultured with hepatocytes into bionic tissue for up to 10 d. Further, microreactors loaded with the liver enzyme catalase are effective in alleviating external pressure, induced by the addition of hydrogen peroxide, from such bionic tissue in an attempt to mimic the detoxification ability of hepatocytes. Taken together, the findings open up a different route in combining synthetic and biological entities for tissue engineering by using the former partner not only as structural support, but also to induce beneficial activity.
Impact of CRi on the Outcome of Elderly Patients with Acute Myeloid Leukemia.
Authors: Anne Etienne, Aude Charbonnier, Thomas Prebet, Diane Coso, Anne-Marie Stoppa, Evelyne D’Incan, Marie-Françoise Doglio, Danièle Sainty, Marie-Joelle Mozziconacci, Jérome Rey, Jean-Albert Gastaut, Norbert Vey
Journal: Blood (2007)
B Cell Lymphoma Unclassifiable, with Features Intermediate Between Diffuse Large B Cell Lymphoma and Burkitt Lymphoma and Diffuse Large B Cell Lymphoma NOS with Doble/Triple Translocations: Immunophenotypic Analysis
Authors: Sonia González de Villambrosia, Mercedes Colorado, Andres Insunza, Ana Batlle, Brenda López-Pereira, Guillermo Martin, Paloma Ibarrondo, Santiago Montes-Moreno, Eulogio Conde
Journal: Blood (2015)
Decitabine Plus Mini Fludarabine and Busulfan Yields Durable Engraftment with Low Relapse Rates in Elderly or Medically Infirm Patients with Myeloid Malignancies
Authors: Melissa F Baker, Scott D Rowley, Stuart L. Goldberg, Anthony R Mato, Andrew L Pecora, David H. Vesole, Phyllis McKiernan, Andre Goy, Michele L. Donato
Journal: Blood (2012)
Immunosuppressive Drugs Upregulate the Immunoinhibitory Receptor Osteoactivin in Monocyte-Derived Dendritic Cells,
Authors: Mark-Alexander Schwarzbich, Michael Gutknecht, Lisa Guettler, Lothar Kanz, Helmut R. Salih, Frank Gruenebach, Susanne Malaika Rittig
Journal: Blood (2011)
HIV-Associated Plasmablastic Lymphoma: A Multi-Institutional Study
Authors: Michael Furman, Pascual Balsalobre, Brady E Beltran, Michele Bibas, Mark Bower, Weina Chen, Silvia Montoto, Roberto N Miranda, Nahid M. Nanaji, Jose-Tomas Navarro, Adam C. Seegmiller, Julie M Vose, Jorge J Castillo
Journal: Blood (2011)
Practically All Patients with Acute Myeloid Leukemia (AML) in Continuous Complete Remission for 3 Years or More Are Cured of Their Disease: The ECOG Experience
Authors: Justin M Watts, Lynette Zickl, Mark R Litzow, Selina M Luger, Hillard M Lazarus, Peter A Cassileth, Hugo F Fernandez, Dan Douer, Elisabeth Paietta, Jacob M Rowe, Martin S Tallman
Journal: Blood (2012)
Treatment Outcome and Quality of Life in Non-Hodgkin's Lymphoma of Intestine: a Multicenter Study of the Consortium for Improving Survival of Lymphoma (CISL).
Authors: Seok Jin Kim, Sukjoong Oh, Chul Won Choi, Soon Il Lee, Hyeong Su Kim, Sung Yong Oh, Jong Ho Won, Jin Seok Kim, Min Kyoung Kim, Hye Jin Kang, Yeung-Chul Mun, Jae-Yong Kwak, Jung Mi Kwon, Jinny Park, Hyo Jung Kim, In Gyu Hwang, Jina Yoon, Jee Hyun Kong, Jung A. Kim, Won Seog Kim, Cheolwon Suh
Journal: Blood (2009)
A Prospective Multicenter Phase II Study by the Puget Sound Oncology Consortium (PSOC) of Gemcitabine (G), Carboplatin (C), Dexamethasone (D), and Rituximab (R) in Patients with Relapsed/Refractory Lymphoma
Authors: Aj ay K Gopal, Oliver W. Press, Andrei Shustov, Stephen Petersdorf, Ted Gooley, Jasmine T. Daniels, Mitchell Garrison, George Gjerset, Matthew Lonergan, Anne Murphy, Julie Smith, John M. Pagel
Journal: Blood (2008)
Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study
Authors: Helen K Reddel, William W Busse, Søren Pedersen, Wan C Tan, Yu-Zhi Chen, Carin Jorup, Dan Lythgoe, Paul M O'Byrne
Journal: The Lancet (2016)
Lack of Significance of ISS Staging and Depth of Response in Predicting Overall Survival for Multiple Myeloma Patients
Authors: Ariana Berenson, Suzie Vardanyan, Michael Ghermezi, Nika M Harutyunyan, Jillian Gottlieb, Ran Halleluyan, Claudia Andreu-Vieyra, Regina A. Swift, James R. Berenson
Journal: Blood (2014)
FcγRIIa and the Integrin β3 Cytoplasmic Domain: Two Prerequisites for Thrombocytopenia and Thrombosis Following Administration of the Fibrinogen Receptor Antagonist, Eptifibatide.
Authors: Cunji Gao, Brian Boylan, Dan Bougie, Briana Nesst, Richard H. Aster, Peter J. Newman
Journal: Blood (2007)
Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study
Authors: Jeanette K Doorduijn, Monique C. Minnema, Marie Jose Kersten, Pieternella J Lugtenburg, Martin R. Schipperus, Marinus van Marwijk Kooy, Marius MacKenzie, Josée M Zijlstra, Henriette W Berenschot, M. R Schaafsma, Dana A Chitu, Hanneke C. Kluin-Nelemans
Journal: Blood (2015)
C/EBPα and C/EBPε Induce Monocytic Differentiation of Myelomonocytic Cells with MLL Chimeric Fusion Gene.
Authors: Hiromichi Matsushita, Hideaki Nakajima, Yoshihiko Nakamura, Hideo Tsukamoto, Yumiko Tanaka, Satomi Asai, Tetsuya Nosaka, Kiyoshi Ando, Hayato Miyachi
Journal: Blood (2006)
Genome-Wide Analysis of Copy Number Alterations/LOH/Allelic Imbalances in Non-Hodgkin Lymphoma Using Ultrahigh-Density SNP-Genotyping Microarrays with the Robust CNAG Algorithms.
Authors: Kumi Nakazaki, Yasuhito Nannya, Masashi Sanada, Go Yamamoto, Chiaki Aoyama, Fumihiko Nakamura, Noriko Hosoya, Lili Wang, Akira Hangaishi, Mineo Kurokawa, Shigeru Chiba, Seishi Ogawa
Journal: Blood (2005)
Genetic and Biochemical Biomarkers of IMPDH Inhibition in Phase I Dose Escalation of AVN-944 for Hematologic Malignancies.
Authors: Jeffrey W. Strovel, Marion Chakiath, Pachai Natarajan, Tammy Lawrence, Karina M. Zuck, Lenore Urbani, Beverly S. Mitchell, David K. Bol
Journal: Blood (2006)
Asn 505 Mutation of the C-MPL Gene, A Cause of Familial Essential Thrombocythemia, Induces the Autonomous Homodimerizaton of the C-Mpl Independent of Ligand Stimulation.
Authors: Jianmin Ding, Hirokazu Komatsu, Shinsuke Iida, Atsushi Wakita, Masakazu Nitta, Hiroshi Miyazaki, Ryuzo Ueda
Journal: Blood (2004)
MTR-06A STRATEGY FOR REDUCING HYPOXIA INDUCED CHEMORESISTANCE IN GLIAL CELLS
Authors: Akansha Jalota, Bhudev C. Das, Ajay K. Yadav, Kunzang Chosdol, Subrata Sinha
Journal: Neuro-Oncology (2015)

BACKGROUND: Glioblastoma multiforme is refractory to conventional treatment, highlighting the need for more efficient therapies. Hypoxia, which is a characteristic feature of glioma is markedly responsible for the chemoresistance. A rational combination of drugs has the possibility of improving therapeutic response. Cisplatin (CP) and 2- Deoxy-D-glucose (2-DG) are not very effective as single agents, and hence we have investigated the efficacy and mechanism of action of their combination in glial tumor cell lines, under both normoxia and hypoxia. METHODS: Cell survival analysis after treatment with combination as compared to single agent was done by MTT assay and combination index calculated. MTT results were confirmed through caspase 3/7 assay and propidium iodide staining. Expression of autophagy, apoptosis, endoplasmic reticulum (ER) stress markers were confirmed through Real time PCR and western blotting. ATP assay was done to investigate the effect on cellular metabolism. RESULTS: The combination of CP and 2-DG was synergistic under normoxia and hypoxia with combination index less than 1. Analysis of caspase 3/7 activity and cell cycle (subG1) along with biomarkers of autophagy and apoptosis indicated switch over from autophagic to apoptotic pathways. Since 2-DG induces autophagy through ER stress, reduction in autophagy by the combination was further confirmed by reduction in ER stress marker under both normoxia and hypoxia. CONCLUSION: The in-vitro study showed the potential of the combination for reducing chemoresistance under both normoxia and hypoxia in glioma cells. Abrogation of the chemoresistance by the combination was through attenuation of autophagy by reduction in ER stress.
Analysis of ADAMTS13 and Its IgG-Autoantibodies in 170 Patients with Connective Tissue Disease-Associated Thrombotic Microangiopathy Indicates More Than 2 Types on Its Pathogenesis.
Authors: Tomomi Matsuyama, Masanori Matsumoto, Ayami Isonishi, Shigeko Inokuma, Yoshihiro Fujimura
Journal: Blood (2007)
Antigen Cross-Presentation Allows the PR1 Leukemia-Associated Antigen To Be Processed from Both Proteinase 3 and Neutrophil Elastase to Prime T Cells.
Authors: Yoko Ono, Yukio Kondo, Anna Sergeeva, Olanike Akande, Pariya Sukhmalchandra, Sijie Lu, Eric Wieder, Jeffrey J. Molldrem
Journal: Blood (2004)
Incidence Trends and Predictors of Hospitalization for Hypoglycemia in 17,230 Adult Patients With Type 1 Diabetes: A Danish Register Linkage Cohort Study
Authors: Kazi Ishtiak-Ahmed, Bendix Carstensen, Ulrik Pedersen-Bjergaard, Marit E. Jørgensen
Journal: Diabetes Care (2016)

This study aimed to examine nationwide incidence trends and predictors of hospitalization for hypoglycemia (HH) in the adult population with type 1 diabetes in Denmark.All 17,230 patients with type 1 diabetes aged 16 years and above registered in the Danish Adult Diabetes Database (DADD) from 2006 were followed to 2012 by linkage of registers. Incidence rates of HH were modeled by Poisson regression by calendar time, taking sex, age, diabetes duration, clinical variables, and previous HH into account.A total of 2,369 events of HH occurred among 1,735 patients with type 1 diabetes of HH during 70,002 patient-years (mean follow-up 3.7 years). A decrease in incidence rate was observed with calendar time with an 8.4% (4.9-11.7%) annual decrease. Predictors of HH included previous HH, age, diabetes duration, albuminuria, and HbA1c.This study revealed a decreasing trend in incidence of HH in patients with type 1 diabetes. Previous HH, longer diabetes duration, macroalbuminuria, and HbA1c were associated with increased risk of HH in type 1 diabetes, and attention to those factors is warranted in both clinical and public health aspects.
Elevated Expression of GPR34 in Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma and Its Association with Increased Cell Growth, Erk Activation, and AP-1 and CRE-Mediated Transcription.
Authors: Anne J Novak, Takashi Akasaka, Michelle Manske, Tammy Price-Troska, Mamta Gupta, Thomas E. Witzig, Martin JS Dyer, Ahmet Dogan, Stephen M Ansell
Journal: Blood (2009)